• P. RAMA Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamilnadu, India
  • R. MONISHA Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamilnadu, India
  • SUSAN VARGHESE PAUL Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamilnadu, India
  • VARSHA ELSA SCARIA Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamilnadu, India
  • P. JANANI Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamilnadu, India
  • SANTHOSH PERUMAL Department of Neurology, PSG Hospitals, Coimbatore, Tamilnadu, India


Objective: To assess the rationale use of benzodiazepines among various departments in a multi-speciality hospital.

Methods: A prospective study was conducted with a sample size of 200 for a period of six months. Data was collected from patients based on inclusion and exclusion criteria. Naranjo Adverse Drug Reaction Probability Scale and Drug Interaction Probability Scale (DIPS) were used as a study tool to measure the causality of adverse drug reactions and drug interactions. Based on the dosage of various benzodiazepines DDD was calculated and compared with WHO Anatomical Therapeutic Chemical (ATC) classification Defined Daily Dose (DDD).

Results: BZD’s were mostly prescribed in males (74.5%) and married patients (86.5%) were more exposed to benzodiazepines compared to others. Lorazepam (70.1%) was found to be the most commonly used drug, mainly prescribed for sedation, followed by anxiety. DDD was calculated and majority of patients had DDD in accordance with WHO standard. Based on cost analysis, Clobazam was found to be the high cost and Lorazepam being the low-cost drug. The results of drug utilization evaluation of benzodiazepines study were compiled and reported to the respected department physician and their feedback was collected.

Conclusion: The study showed a rational utilization of benzodiazepines and the negative outcomes of BZDs can be reduced by providing drug-related information to the prescribers and consumers.

Keywords: Benzodiazepines, Drug utilization, Naranjo adverse drug reaction scale, DIPS, DDD


Download data is not yet available.


1. Tjagvad C, Clausen T, Handal M, Skurtveit S. Benzodiazepine prescription for patients in treatment for drug use disorders: a nationwide cohort study in denmark, 2000–2010. BMC Psychiatry 2016;16:168.
2. Banerjee I, Roy B, Sathian B, Banerjee I, Kumar SS, Saha A. Medications for anxiety: a drug utilization study in psychiatry inpatients from a tertiary care centre of western Nepal Nepal. J Epidemiol 2011;1:119-25.
3. Nakao M, Sato M, Nomura K, Yano E. Benzodiazepine prescription and length of hospital stay at a Japanese university hospital. BioPsychoSocial Med 2009;3:10.
4. Kharadi D, Patel K, Rana D, Patel V. Off-label drug use in psychiatry outpatient department: a prospective study at a tertiary care teaching hospital. J Basic Clin Pharm 2015;6:45.
5. Mittal N, Mittal R, Singh I, Shafiq N, Malhotra S. Drug utilisation study in a tertiary care center: recommendations for improving hospital drug dispensing policies. Indian J Pharm Sci 2014;76:308.
6. Guina J, Merrill B. Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives. J Clin Med 2018;7:17.
7. Ismail M, Iqbal Z, Khattak MB, Javaid A, Khan MI, Khan TM, et al. Potential drug-drug interactions in the psychiatric ward of a tertiary care hospital: prevalence, levels and association with risk factors. Trop J Pharm Rese 2012;11:289-96.
8. Van Hulten R, Teeuw B, Bakker A, Leufkens HG. Initial benzodiazepine use and improved health-related quality of life. Pharm World Sci 2005;27:41-6.
9. Jainaf Nachiya RA, Parimalakrishnan S, Ramakrishna Rao M. Study on drug utilization pattern of antihypertensive medications on out-patients and inpatients in a tertiary care teaching hospital: a cross-sectional study. Afr J Pharm Pharmacol 2015;9:383-96.
10. Mateti UV, Prabhakaran P, Sanal TS. Utilization patterns of benzodiazepines in psychiatric patients in a tertiary care teaching hospital. Asia Pacific J Clin Trials: Nervous System Diseases 2016;1:196.
11. Ramadan WH, El Khoury GM, Deeb ME, Sheikh Taha M. Prescription patterns of benzodiazepines in the lebanese adult population: a cross-sectional study. Neuropsychiatr Dis Treat 2016;12:2299.
12. Javaheri S, Redline S. Insomnia and risk of cardiovascular disease. Chest 2017;152:435-44.
13. Mendelson WB, Thompson C, Franko T. Adverse reactions to sedative/hypnotics: three years’ experience. Sleep 1996;19:702-6.
14. Itil T, Shapiro D, Itil KZ, Eralp E, Bergamo M, Mucci A. Discrimination of mode of action of anxiolytics using an integrated computer data bank and dynamic brain mapping: CNS effects of diazepam and lorazepam. Int Clin Psychopharmacol 1989;4:273-83.
15. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry 2015;72:136-42.
16. Kaplan EM, DuPont RL. Benzodiazepines and anxiety disorders: a review for the practicing physician. Curr Med Res Opinion 2005;21:941-50.
524 Views | 336 Downloads
How to Cite
RAMA, P., R. MONISHA, S. V. PAUL, V. E. SCARIA, P. JANANI, and S. PERUMAL. “DRUG UTILIZATION EVALUATION OF BENZODIAZEPINES IN A TERTIARY CARE HOSPITAL”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 11, no. 11, Nov. 2019, pp. 6-9, doi:10.22159/ijpps.2019v11i11.35359.
Original Article(s)